AU1990195A - Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer - Google Patents
Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancerInfo
- Publication number
- AU1990195A AU1990195A AU19901/95A AU1990195A AU1990195A AU 1990195 A AU1990195 A AU 1990195A AU 19901/95 A AU19901/95 A AU 19901/95A AU 1990195 A AU1990195 A AU 1990195A AU 1990195 A AU1990195 A AU 1990195A
- Authority
- AU
- Australia
- Prior art keywords
- medicament
- cancer
- inhibit
- compounds
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20876594A | 1994-03-08 | 1994-03-08 | |
| US208765 | 1994-03-08 | ||
| PCT/US1995/003081 WO1995024199A2 (en) | 1994-03-08 | 1995-03-08 | Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1990195A true AU1990195A (en) | 1995-09-25 |
Family
ID=22775965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU19901/95A Abandoned AU1990195A (en) | 1994-03-08 | 1995-03-08 | Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0708645A1 (en) |
| AU (1) | AU1990195A (en) |
| CA (1) | CA2166324A1 (en) |
| WO (1) | WO1995024199A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0573617A1 (en) * | 1991-05-24 | 1993-12-15 | Fred Hutchinson Cancer Research Center | Modulation of cellular response to external stimuli |
| US5288721A (en) * | 1992-09-22 | 1994-02-22 | Cell Therapeutics, Inc. | Substituted epoxyalkyl xanthines |
| IL109161A0 (en) * | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
-
1995
- 1995-03-08 AU AU19901/95A patent/AU1990195A/en not_active Abandoned
- 1995-03-08 WO PCT/US1995/003081 patent/WO1995024199A2/en not_active Application Discontinuation
- 1995-03-08 CA CA002166324A patent/CA2166324A1/en not_active Abandoned
- 1995-03-08 EP EP95912888A patent/EP0708645A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995024199A2 (en) | 1995-09-14 |
| CA2166324A1 (en) | 1995-09-14 |
| EP0708645A1 (en) | 1996-05-01 |
| WO1995024199A3 (en) | 1995-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU5384096A (en) | Use of vitamin D2 or vitamin D4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism | |
| AU4715796A (en) | Use of carotinoids for preparing medicaments for treating dermatoses | |
| AU2805195A (en) | Therapeutic compounds | |
| AU6165894A (en) | Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth | |
| AU5802196A (en) | Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers | |
| AU7622000A (en) | Compounds for the treatment of viral-mediated diseases | |
| AU5801996A (en) | Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers | |
| AU2508597A (en) | Drug for the treatment of tumours | |
| EP0686395A3 (en) | Use of hyaluronic acid for the manufacture of a medicament for the inhibition of platelet aggregation | |
| AU1578395A (en) | Use of insulin sensitisers for treating renal diseases | |
| EP0765663A3 (en) | Use of dienogest for the manufacture of a medicament for the treatment of the skin by topical application | |
| AU7269294A (en) | Use of glucokinase inhibitors for the manufacture of a medicament for treating tumours | |
| AU3728095A (en) | Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis | |
| AU3187595A (en) | Compounds for the treatment of restenosis | |
| AU9173191A (en) | Medicaments for the treatment of papillomavirus diseases | |
| AU3810495A (en) | Process for the manufacture of n-phosphonomethylglycine | |
| EP0765661A3 (en) | Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis | |
| AU2787495A (en) | Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis | |
| AU3684395A (en) | Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases | |
| AU2739497A (en) | Use of vitamin d analogs for the treatment of arthritic disease | |
| AU7982098A (en) | Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis | |
| AU1348895A (en) | Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders | |
| IL121329A0 (en) | A pharmaceutical composition for the treatment of cancer | |
| AU1990195A (en) | Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer | |
| AU5627796A (en) | Medicaments for the treatment or prophylaxis of ischemia-reperfusion injury |